Skip to content
HowShorted

ASSEMBLY BIOSCIENCES, INC. short interest in 2023

In 2023, ASSEMBLY BIOSCIENCES, INC.'s disclosed short interest ran from 0.32% of shares outstanding on 31 Mar 2023 to 0.31% on 29 Dec 2023, a change of -0.01 percentage points. The year's high was 1.20% on 31 Oct 2023 and its low 0.24% on 31 Aug 2023, averaging 0.46% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.50 days on 31 May 2023. Full history: ASSEMBLY BIOSCIENCES, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ASSEMBLY BIOSCIENCES, INC. in 2023

2023 in figures

Start of year
0.32% (31 Mar 2023)
End of year
0.31% (29 Dec 2023)
Change
-0.01 pp
High
1.20% (31 Oct 2023)
Low
0.24% (31 Aug 2023)
Average
0.46%
Highest days to cover
2.50 (31 May 2023)
SEC filings marked
8

Every report in 2023

ASSEMBLY BIOSCIENCES, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
31 Mar 20230.32%1.0010-K filed, results (8-K)
14 Apr 20230.58%1.09
28 Apr 20230.33%1.00
15 May 20230.31%1.5910-Q filed, results (8-K)
31 May 20230.55%2.50
15 Jun 20230.57%2.42
30 Jun 20230.31%1.70
14 Jul 20230.32%1.96
31 Jul 20230.36%1.73
15 Aug 20230.30%1.7310-Q filed, results (8-K)
31 Aug 20230.24%1.41
15 Sep 20230.27%1.97
29 Sep 20230.26%1.04
13 Oct 20230.26%1.00
31 Oct 20231.20%1.00
15 Nov 20230.99%1.0010-Q filed, results (8-K)
30 Nov 20230.80%1.00
15 Dec 20230.39%1.00
29 Dec 20230.31%1.00

See also: ASSEMBLY BIOSCIENCES, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.